Nucleoside RT Inhibitor (NRTI) Resistance Mutations: Percent Occurrence in Patients Treated with Dual NRTI plus Nonnucleoside RT Inhibitor (NNRTI) First-Line Antiretroviral (ARV) Regimens.

Footnote: *No.: Number of patients receiving first-line therapy with the ARV regimen indicated in the first two columns. †Although M184V/I is a discriminatory mutation it is shown separately because it is the single most common mutation. §The proportion of individuals receiving a thymidine analog (d4T or AZT) or non-thymidine analog (TDF or ABC) based regimen having the indicated mutation. Mutations for which there were statistically significant differences between these proportions are in bold, *p≤0.01, **p≤0.001.